Teacher Retirement System of Texas Sells 447,650 Shares of Hologic, Inc. (NASDAQ:HOLX)

Teacher Retirement System of Texas lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 68.9% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 202,233 shares of the medical equipment provider's stock after selling 447,650 shares during the period. Teacher Retirement System of Texas owned approximately 0.09% of Hologic worth $12,492,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Hologic in the 4th quarter worth approximately $49,000. West Financial Advisors LLC purchased a new position in shares of Hologic in the 1st quarter worth approximately $50,000. Finally, Briaud Financial Planning Inc purchased a new position in shares of Hologic in the 4th quarter worth approximately $72,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HOLX shares. Royal Bank Of Canada cut their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James Financial restated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Evercore ISI upped their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Hologic has a consensus rating of "Hold" and an average target price of $77.92.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction on Wednesday, May 7th. The shares were acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

HOLX stock traded up $0.53 during midday trading on Tuesday, reaching $64.90. 2,280,030 shares of the company's stock traded hands, compared to its average volume of 2,381,169. The company has a 50-day moving average price of $60.97 and a two-hundred day moving average price of $63.61. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The firm has a market capitalization of $14.46 billion, a PE ratio of 27.38, a price-to-earnings-growth ratio of 2.36 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the firm posted $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.